New weight-based dosing for ribavirin available for hepatitis C patients
Schering-Plough has announced that FDA has approved a 1,400-mg dose of ribavirin and recommended that it be dosed based on patient weight.
Treating chronic hepatitis C virus (HCV) patients with heavy weights used to be a problem for clinicians. Now a new solution is available from Schering-Plough Corp-a 1,400-mg dose of REBETOL (ribavirin, USP). The Food & Drug Administration has approved label revisions for PEGINTRON (peginterferon alfa-2b, Schering-Plough) and ribavirin combination therapy, recommending dosing of ribavirin (800-1400 mg daily) based on patient body weight. The revised label also suggests a shorter, 24-week course of the combination therapy for HCV patients with genotype 2 or 3. The Kenilworth, N.J., firm claims that the labeling changes are based on the results of the largest U.S. hepatitis C study, WIN-R trial, which covered more than 4,900 patients.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
